Alpha Teknova, Inc. (Teknova) is a biotechnology company specializing in the production of critical reagents for bioprocessing, bioproduction, and molecular diagnostics. Founded in 1996 by former Genentech scientist Ted Davis, the company is headquartered in Hollister, California. Teknova's mission is to expedite clinical breakthroughs in the life sciences by providing high-quality, custom-made products that support the discovery, development, and commercialization of novel therapies. The company's offerings include cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents, catering to applications such as cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology.
Strategically, Teknova focuses on delivering customizable, high-quality reagents with rapid turnaround times to meet the evolving needs of the life sciences industry. The company's proprietary modular manufacturing platform allows for the efficient production of both research-grade and Good Manufacturing Practice (GMP) products, enabling seamless scaling from research to clinical manufacturing. Teknova targets markets including cell and gene therapy, vaccine production, and molecular diagnostics, positioning itself as a key supplier in these rapidly growing sectors.
As of April 29, 2025, Teknova's stock (NASDAQ: TKNO) is trading at $6.71 per share, with a market capitalization of approximately $376.3 million. The company has raised a total of $96 million in funding over one round and is publicly traded. In July 2024, Teknova completed a private placement, generating gross proceeds of approximately $15.4 million to support operational growth and enhance manufacturing capabilities.
Teknova's product pipeline includes a range of reagents and solutions designed to support various stages of therapeutic development. Notably, the company has collaborated with Pluristyx to manufacture and distribute the PluriFreeze™ cryopreservation system, aimed at streamlining the production of allogeneic cell therapies. This partnership underscores Teknova's commitment to providing innovative solutions that address critical bottlenecks in cell therapy manufacturing.
Teknova's proprietary modular manufacturing platform is a key differentiator, enabling the rapid production of custom, made-to-order products at scale. This platform allows for flexibility and precision, accommodating the specific needs of clients across various stages of development, including commercialization. Additionally, the company's commitment to sustainability is evident through initiatives such as developing recycling and quality control protocols for a reuse program and re-engineering packaging formats to reduce environmental impact.
The leadership team at Teknova comprises experienced professionals dedicated to advancing the company's mission:
- Stephen Gunstream, Chief Executive Officer
- Lisa McCann, Chief People Officer
- Ken Gelhaus, Chief Commercial Officer
- Matt Lowell, Chief Financial Officer
These executives bring a wealth of experience in the life sciences industry, guiding Teknova's strategic initiatives and operational growth.
In March 2025, Teknova announced a strategic collaboration with Pluristyx, becoming the exclusive manufacturer and distributor of the PluriFreeze™ product line in the United States and Canada. This partnership aims to streamline the manufacture of next-generation allogeneic cell therapies by providing a novel cryopreservation system that simplifies the scale-up process for cell therapy developers.
Teknova operates in a competitive landscape alongside companies such as New England Biolabs, Bioline, Biological Industries, Irvine Scientific, and Active Motif. These competitors offer similar products and services in the life sciences sector, including reagents, media, and diagnostic solutions. Teknova differentiates itself through its focus on customization, rapid turnaround times, and a modular manufacturing platform that allows for scalability and flexibility.
Teknova's strategic collaborations, such as the partnership with Pluristyx, enhance its market position by expanding its product offerings and addressing critical needs in the cell therapy sector. These alliances enable Teknova to leverage complementary technologies and expertise, fostering innovation and growth.
Teknova's operational strategy focuses on maintaining a competitive edge through its modular manufacturing platform, which allows for rapid customization and scalability. This approach enables the company to meet the specific needs of clients across various stages of development, from research to commercialization. Additionally, Teknova's commitment to sustainability and quality assurance further strengthens its market position.
Looking ahead, Teknova aims to expand its product offerings and manufacturing capabilities to meet the growing demands of the life sciences industry. The company's focus on customization, rapid turnaround times, and strategic collaborations positions it well to capitalize on emerging opportunities in bioprocessing, bioproduction, and molecular diagnostics. By leveraging its strengths and addressing industry needs, Teknova is poised for continued growth and innovation.
For more information, visit Teknova's official website.
Note: Specific contact details such as email addresses and phone numbers have been omitted in accordance with the provided instructions.
